KALRAY
5.7.2022 18:02:03 CEST | Business Wire | Press release
Clever Cloud , a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/
Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution.
PERFORMANCE, RESILIENCE AND OPENNESS
Without a host CPU (Central Processing Unit), the Flashbox™ leverages K200-LP™ accelerator cards featuring the Coolidge™ DPU (Data Processing Unit) that takes advantage of the unique and patented MPPA® (Massively Parallel Processor Array) architecture developed by Kalray. This chip takes advantage of the power of 80 parallel cores and enables data centers adopting NVMe SSD storage to remove bottlenecks and improve performance, while consuming minimal power and resources.
A unique concept on the market today, the Flashbox™ as proposed by Kalray benefits from ultra-fast interfaces and low power consumption. It can deliver up to 12 million IOPS through a 2x 100 Gb/s network interface and is based on market standards such as Storage Performance Development Kit (SPDK), NVMe/TCP or RDMA over Converged Ethernet (RoCEv1/v2). It will eventually be offered by storage vendors using Kalray cards.
"Kalray's solution meets all our needs and the criteria that are important to us, whether in terms of sovereignty, openness, resilience, energy efficiency or performance ," said Quentin Adam, CEO of Clever Cloud.
The Flashbox™ is currently being tested in Clever Cloud's infrastructure and will join its new Paris data center where it will work alongside the latest generation of compute servers Clever Cloud is installing there. It will enable Clever Cloud to offer greater flexibility to its customers in managing storage, but also to support the launch of new offerings.
This is part of the development of Clever Cloud's Storage API, which allows various storage sources, whether local, remote or via third-party cloud service providers, to be simply allocated to the virtual machines that host users' applications. This open, multi-cloud approach is what makes Clever Cloud so successful.
CLEVER CLOUD AND KALRAY: FOR A “MADE IN FRANCE” R&D
Clever Cloud and Kalray are also partnering in several projects where they are working closely together to leverage Kalray's K200-LP™ cards as accelerators to offload Clever Cloud's network layer functionalities or computations related to the protection and redundancy of data stored within Clever Cloud's servers.
"The collaboration with Kalray is not just about two French companies that have an interest in working together, but about two projects that have, at their heart, the creation of value through innovation, where the partnership is also between the technical teams," adds Steven Le Roux, CTO of Clever Cloud .
“We are very pleased to be working with Clever Cloud, with whom we share common values, both in terms of innovation and the philosophy of our solutions, which are designed to be easy to use, flexible, scalable and open.
Kalray has a unique position in Europe in this market of very high-performance and low-power processors. We are proud to be able to build innovative French storage solutions with Clever Cloud and thus contribute to the technological sovereignty of France and Europe” , declares Eric Baissus, President and CEO of Kalray .
The Flashbox™ will be showcased at the upcoming Flash Memory Summit, a major event in the field, from August 2 to 4, 2022, in Santa Clara Convention Center, CA, USA (booth #940).
ABOUT CLEVER CLOUD
Founded in 2010, Clever Cloud is a company based in Nantes, France, and specialized in IT automation. It creates and provides the software building blocks necessary for the flexible deployment of applications on self-service PaaS architectures. Its clients include such major names as Airbus, AXA, Caisse d'Épargne, Cegid, Docaposte, MAIF, McDonald's, Solocal, SNCF, TBWA...
Website: https://www.clever-cloud.com
Latest news: https://www.clever-cloud.com/blog
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005197/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom